EGFR and non-small cell lung carcinoma: Considering a range of concentrations for pembrolizumab from 0.12 to 2μM, based on the described IC50 values of pembrolizumab in the inhibition of cell proliferation of the NSCLC A549 cell line (EGFR wt) (IC50 = 0.4 μM) (44), we treated NSCLC cell lines concomitantly with SFRE at a fixed dose of 1/2 IC50.